470 related articles for article (PubMed ID: 27170339)
21. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
Fishbane S; Frei GL; Maesaka J
Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266
[TBL] [Abstract][Full Text] [Related]
22. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
23. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
24. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.
Gaweda AE; Goldsmith LJ; Brier ME; Aronoff GR
Clin J Am Soc Nephrol; 2010 Apr; 5(4):576-81. PubMed ID: 20110344
[TBL] [Abstract][Full Text] [Related]
25. Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients.
Fusaro M; Munaretto G; Spinello M; Rebeschini M; Amici G; Gallieni M; Piccoli A
J Nephrol; 2005; 18(1):72-9. PubMed ID: 15772926
[TBL] [Abstract][Full Text] [Related]
26. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO).
Saltissi D; Sauvage D; Westhuyzen J
Clin Nephrol; 1998 Jan; 49(1):45-8. PubMed ID: 9491286
[TBL] [Abstract][Full Text] [Related]
27. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
Li H; Wang SX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
[TBL] [Abstract][Full Text] [Related]
28. Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency.
Brătescu LO; Bârsan L; Gârneaţă L; Stanciu A; Lipan M; Stancu SH; Mircescu G
Int Urol Nephrol; 2014 May; 46(5):1005-12. PubMed ID: 24800994
[TBL] [Abstract][Full Text] [Related]
29. A randomized controlled study of iron supplementation in patients treated with erythropoietin.
Macdougall IC; Tucker B; Thompson J; Tomson CR; Baker LR; Raine AE
Kidney Int; 1996 Nov; 50(5):1694-9. PubMed ID: 8914038
[TBL] [Abstract][Full Text] [Related]
30. Erythropoietin requirement in patients with type 2 diabetes mellitus on maintenance hemodialysis therapy.
Biesenbach G; Schmekal B; Eichbauer-Sturm G; Janko O
Wien Klin Wochenschr; 2004 Dec; 116(24):844-8. PubMed ID: 15690969
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of erythropoiesis on supervised intradialytic oral iron and vitamin C therapy is correlated with Kt/V and patient weight.
Tovbin D; Markowitz A; Mostoslavsky M; Landver R
Clin Nephrol; 2000 Apr; 53(4):276-82. PubMed ID: 10809415
[TBL] [Abstract][Full Text] [Related]
32. Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients.
Kumar VA; Kujubu DA; Sim JJ; Rasgon SA; Yang PS
J Nephrol; 2011; 24(1):98-105. PubMed ID: 20563998
[TBL] [Abstract][Full Text] [Related]
33. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.
Ogawa C; Tsuchiya K; Tomosugi N; Kanda F; Maeda K; Maeda T
PLoS One; 2017; 12(6):e0179608. PubMed ID: 28662118
[TBL] [Abstract][Full Text] [Related]
34. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
[TBL] [Abstract][Full Text] [Related]
35. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
36. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.
Kakimoto-Shino M; Toya Y; Kuji T; Fujikawa T; Umemura S
Ther Apher Dial; 2014 Oct; 18(5):421-6. PubMed ID: 24456328
[TBL] [Abstract][Full Text] [Related]
37. Administration of the same dose of epoetin-beta intravenously and subcutaneously to patients with renal anaemia.
Steffensen GK; Stergaard O
Scand J Urol Nephrol; 2011 Dec; 45(6):461-9. PubMed ID: 21736448
[TBL] [Abstract][Full Text] [Related]
38. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
Riedel MK; Morgenstern T
Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
[TBL] [Abstract][Full Text] [Related]
39. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients.
Daschner M; Mehls O; Schaefer F
Clin Nephrol; 1999 Oct; 52(4):246-52. PubMed ID: 10543327
[TBL] [Abstract][Full Text] [Related]
40. A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients.
Johnson DW; Herzig KA; Gissane R; Campbell SB; Hawley CM; Isbel NM
Nephrol Dial Transplant; 2001 Sep; 16(9):1879-84. PubMed ID: 11522873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
